Medaxone 1 g

A III generation cephalosporin antibiotic for parenteral use. It has bactericidal action, inhibits cell membrane synthesis, in vitro suppresses growth of most gram-positive and gram-negative microorganisms. Ceftriaxone is resistant to β-lactamases (both penicillinase and cephalosporinase produced by most Gram-positive and Gram-negative bacteria).

The drug is active against Gram-positive microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus A (Streptococcus pyogenes), Streptococcus V (Streptococcus agalactiae), Streptococcus viridans, Streptococcus bovis.

The drug is active against Gram-negative microorganisms:Aeromonas spp., Alcaligenes spp., Branhamella catarrhalis, Citrobacter spp, Enterobacter spp. (some strains are resistant), Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebssiella spp. (including Klebssiella pneumoniae), Moraxella spp, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Plesiomonas shigelloides, Proteus mirabilis, Proteus vulgaris, Providencia spp., Pseudomonas aeruginosa (some strains are resistant), Salmonella spp., Vibrio spp., (incl. Vibrio cholerae), Yersinia spp., (incl. Yersinia Enterocolitica).

Many strains of the listed gram-negative microorganisms, which in the presence of other antibiotics, such as penicillins, first generation cephalosporins and aminoglycosides, reproduce stably, are sensitive to ceftriaxone.

Treponema pallidum is sensitive to ceftriaxone both in vitro and in animal experiments. Clinical data in primary and secondary syphilis show good efficacy of ceftriaxone.

The drug is active against anaerobic microorganisms: Bacteroides spp. (including some strains of Bacteroides fragilis), Clostridium spp. (including Clostridium difficile), Fusobacterium spp. (except Fusobacterium mostiferum, Fusobacterium varium), Peptococcus spp, Peptostreptococcus spp.

The following are resistant to the drug: Staphylococcus strains resistant to methicillin; most strains of enterococci (for example, Streptococcus faecalis); some strains of many Bacteroides (for example, Bacteroides fragilis) that produce β-lactamase (to determine the sensitivity of microorganisms it is necessary to use disks containing ceftriaxone, because it is shown in vitro.because it has been shown that in vitro certain strains of pathogens can be resistant to classical cephalosporins).

Indications

Infectious inflammatory diseases caused by microorganisms sensitive to the drug:

Prevention of infections in the postoperative period.

Active ingredient

How to take, the dosage

The drug is used intramuscularly and intravenously.
For adults and for children over 12 years
The average daily dose is 1-2 g ceftriaxone once a day (after 24 hours).
In severe cases or in cases of infections caused by moderately sensitive pathogens, the single daily dose can be increased to 4 g.

In newborns
For single daily dosage, the following regimen is recommended:
For newborns (up to two weeks of age): 20-50 mg/kg body weight per day (the dose of 50 mg/kg body weight should not be exceeded due to the immature enzyme system of newborns).

In infants and children under 12 years of age
The daily dose is 20-75 mg/kg of body weight.

In children with a body weight of 50 kg or more, the dosage for adults should be followed. A dose greater than 50 mg/kg body weight should be administered as an intravenous infusion for at least 30 minutes.
Duration of therapy – Depends on the course of the disease.

Meningitis
In bacterial meningitis in infants and children, the initial dose is 100 mg/kg body weight once daily (maximum 4 g). Once the pathogenic microorganism has been isolated and its sensitivity determined, the dose should be reduced accordingly.
The best results were achieved with the following terms of therapy:

Special Instructions

Contraindications

Side effects

Overdose

Similarities